Universal Cells

Executive Summary

Universal Cells is a Seattle-based biotechnology company pioneering allogeneic cell therapy through its proprietary nuclease-free gene editing platform. By engineering 'universal donor' induced pluripotent stem cells (iPSCs) that evade immune rejection, the company aims to develop off-the-shelf cell therapies scalable for widespread patient access. Its technology has the potential to address major bottlenecks in cell therapy, including high cost, manufacturing complexity, and immune compatibility. While Universal Cells remains private and has not disclosed recent funding or clinical milestones, its innovative approach to creating hypoimmunogenic cells positions it as a key player in the emerging off-the-shelf cell therapy space. The company's ability to advance toward the clinic and secure strategic partnerships will be critical for near-term value creation. As of early 2026, Universal Cells is at a preclinical stage, with its lead programs likely targeting oncology and regenerative medicine indications.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead iPSC-derived cell therapy candidate45% success
• H2 2026Partnership or licensing deal with a major pharmaceutical company35% success
• Q3 2026Series B or C financing round to support clinical development50% success